Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990–2006

Lin, Robert Y.; Anderson, Ashley S.; Shah, Shaili; Nurruzzaman, Farzana

doi:10.1016/s1081-1206(10)60315-8

Cited by 197 publications

(125 citation statements)

References 36 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…A US nation-wide survey of emergency departments (in 1993-2004) (15) revealed an average of 1.03 million cases per year of allergy-related emergency department visits, representing a mean annual incidence of 0.38% of the US population. Lin et al (16) conducted an analysis of New York state hospital admissions (in 1990-2006) of patients aged <20 years with an allergic disease as the primary diagnosis. The hospitalization rate for anaphylaxis increased more than fourfold during the studied period (from 1/100 000 to 4.7/100 000).…”

Section: Prevalencementioning

confidence: 99%

Anaphylaxis treatment: current barriers to adrenaline auto-injector use

Song

Worm

Lieberman

2014

Allergy

View full text Add to dashboard Cite

To cite this article: Song TT, Worm M, Lieberman P. Anaphylaxis treatment: current barriers to adrenaline auto-injector use. AbstractAnaphylaxis is a life-threatening condition that is increasing in prevalence in the developed world. There is universal expert agreement that rapid intramuscular injection of adrenaline is life-saving and constitutes the first-line treatment of anaphylaxis. The unpredictable nature of anaphylaxis and its rapid progression makes necessary the availability of a portable emergency treatment suitable for self-administration. Thus, anaphylaxis treatment guidelines recommend that at-risk patients are provided with adrenaline auto-injectors (AAIs). Despite these clear recommendations, current emergency treatment of anaphylaxis continues to be inadequate in many cases. The aim of this review is to highlight the barriers that exist to the use and availability of AAIs and that prevent proper management of anaphylaxis. In addition, we review the characteristics of all AAIs that are presently available in Europe and the USA and discuss the need for regulatory requirements to establish the performance characteristics of these devices.

show abstract

Section: Prevalencementioning

confidence: 99%

Anaphylaxis treatment: current barriers to adrenaline auto-injector use

Song

Worm

Lieberman

2014

Allergy

View full text Add to dashboard Cite

show abstract

“…1 The incidence of anaphylaxis has dramatically increased over the past decade, [2][3][4][5][6][7][8][9] with more cases occurring in the community setting than in the hospital setting. 10 Early diagnosis of anaphylaxis and treatment with adrenaline is essential to prevent fatalities, and deaths are more common in patients with a history of asthma.…”

Section: Introductionmentioning

confidence: 99%

Long-term Effectiveness of Online Anaphylaxis Education for Pharmacists

Salter

Vale

Sanfilippo

et al. 2014

American Journal of Pharmaceutical Education

View full text Add to dashboard Cite

Objective. To evaluate the long-term effectiveness of an Australasian Society of Clinical Immunology and Allergy (ASCIA) anaphylaxis e-learning program compared to lectures or no training. Design. A controlled interrupted-time-series study of Australian pharmacists and pharmacy students who completed ASCIA anaphylaxis e-learning or lecture programs was conducted during 2011-2013. Effectiveness was measured using a validated test administered pretraining, posttraining, and 3 and 7 months after training. Assessment. All learning groups performed significantly better on all posttests compared to the pretest, and compared to a control group (p,0.001). The proportion of e-learners achieving the minimum standard for anaphylaxis knowledge improved from 45% at pretest to 87% at 7 months. Conclusion. The ASCIA e-learning program significantly increased anaphylaxis knowledge. The high proportion of participants achieving the minimum standard at 7 months indicates long-term knowledge change.

show abstract

“…Their findings suggest that the incidence of anaphylaxis is increasing in that population, in both children and adults. Others have reported similar trends in the incidence of anaphylaxis overall and, more specifically, food-related anaphylaxis [6][7][8].…”

Section: Introductionmentioning

confidence: 61%

“…In a nearly global manner and for reasons not fully understood, the incidence of anaphylaxis has increased [3][4][5], as has its severity [6][7][8]. This explains the growing interest in epidemiological surveys to map the problem in several populations.…”

Section: Discussionmentioning

confidence: 99%

Who has anaphylaxis in Brazil? Validation of a questionnaire for population studies

Gagete¹,

Santos²,

Pontes³

et al. 2017

World Allergy Organization Journal

View full text Add to dashboard Cite

Background: The incidence of anaphylaxis is increasing in several parts of the world; thus, determining the prevalence of the disease in a given region is important to understand the factors involved and to promote measures to avoid this type of allergic reaction. Aiming this objective, we validated an instrument for a populationbasedstudy that assesses the prevalence of anaphylaxis in the Brazilian population. Methods: A questionnaire was generated in two variants -one for subjects seven years old or above (Group A) and another for children who were up to six years, 11 months and 29 days (Group B). The instrument was administered to patients with and without anaphylaxis. By allocating points, a score was calculated to differentiate subjects with and without the disease. After validation, the questionnaire was applied in the city of Botucatu (São Paulo state, Brazil), by randomly selecting houses and inviting residents to answer the questionnaire. Results: The questionnaire was reliable for identifying subjects with and without anaphylaxis in both groups, with a specificity and sensitivity above 90%. The prevalence of anaphylaxis in the pilot survey was 6.2% in Group A, however the evaluation was compromised in Group B by the low number of children below seven years of age due to random sampling of residences. Discussion: The prevalence of anaphylaxis in our pilot test (6.2%) was similar to major epidemiological surveys from several parts of the world, showing that anaphylaxis is not a rare disease. The instrument of the present work was suitable for this epidemiological survey and might be a good option for studying anaphylaxis in other populations. Conclusion: This instrument might be of particular value in places where researchers cannot access medical records to conduct similar epidemiological studies.

show abstract

Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990–2006

Cited by 197 publications

References 36 publications

Anaphylaxis treatment: current barriers to adrenaline auto-injector use

Anaphylaxis treatment: current barriers to adrenaline auto-injector use

Long-term Effectiveness of Online Anaphylaxis Education for Pharmacists

Who has anaphylaxis in Brazil? Validation of a questionnaire for population studies

Contact Info

Product

Resources

About